Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]Pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 2

被引：4

作者：

Kaieda, Akira ^{[1
]}

Takahashi, Masashi ^{[1
]}

Fukuda, Hiromi ^{[1
]}

Okamoto, Rei ^{[1
]}

Morimoto, Shinji ^{[1
]}

Gotoh, Masayuki ^{[1
]}

Miyazaki, Takahiro ^{[1
]}

Hori, Yuri ^{[1
]}

Unno, Satoko ^{[1
]}

Kawamoto, Tomohiro ^{[1
]}

Tanaka, Toshimasa ^{[1
]}

Itono, Sachiko ^{[1
]}

Takagi, Terufumi ^{[1
]}

Sugimoto, Hiroshi ^{[1
]}

Okada, Kengo ^{[1
]}

Lane, Weston ^{[2
]}

Sang, Bi-Ching ^{[2
]}

Saikatendu, Kumar ^{[2
]}

Matsunaga, Shinichiro ^{[1
]}

Miwatashi, Seiji ^{[1
]}

机构：

[1] Takeda Pharmaceut Co Ltd, Div Pharmaceut Res, 26-1 Muraoka Higashi 2 Chome, Fujisawa, Kanagawa 2518555, Japan

[2] Takeda Calif, 10410 Sci Ctr Dr, San Diego, CA 92121 USA

来源：

CHEMMEDCHEM | 2019年 / 14卷 / 24期

基金：

美国国家卫生研究院;

关键词：

p38 mitogen-activated protein kinase inhibitors; rheumatoid arthritis; structure-based design; imidazo[4; 5-b]pyridin-2-one derivatives; ACTIVATED PROTEIN-KINASE; RHEUMATOID-ARTHRITIS; ANTIRHEUMATIC DRUGS; DOUBLE-BLIND; ALPHA; DISCOVERY; POTENT; EXPRESSION; ANTIBODY; PATHWAY;

D O I：

10.1002/cmdc.201900373

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We identified novel potent inhibitors of p38 mitogen-activated protein (MAP) kinase using a structure-based design strategy, beginning with lead compound, 3-(butan-2-yl)-6-(2,4-difluoroanilino)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one (1). To enhance the inhibitory activity of 1 against production of tumor necrosis factor-alpha (TNF-alpha) in human whole blood (hWB) cell assays, we designed and synthesized hybrid compounds in which the imidazo[4,5-b]pyridin-2-one core was successfully linked with the p-methylbenzamide fragment. Among the compounds evaluated, 3-(3-tert-butyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-6-yl)-4-methyl-N-(1-methyl-1H-pyrazol-3-yl)benzamide (25) exhibited potent p38 inhibition, superior suppression of TNF-alpha production in hWB cells, and also significant in vivo efficacy in a rat model of collagen-induced arthritis (CIA). In this paper, we report the discovery of potent, selective, and orally bioavailable imidazo[4,5-b]pyridin-2-one-based p38 MAP kinase inhibitors.

引用

页码：2093 / 2101

页数：9

共 50 条

[21] Amide-based inhibitors of p38α MAP kinase. Part 2: Design, synthesis and SAR of potent N-pyrimidyl amides
Tester, Richland
Tan, Xuefei
Luedtke, Gregory R.
Nashashibi, Imad
Schinzel, Kurt
Liang, Weiling
Jung, Joon
Dugar, Sundeep
Liclican, Albert
Tabora, Jocelyn
Levy, Daniel E.
Do, Steven
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (08) : 2560 - 2563
[22] Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors
Baladi, Tom
Aziz, Jessy
Dufour, Florent
Abet, Valentina
Stoven, Veronique
Radvanyi, Francois
Poyer, Florent
Wu, Ting-Di
Guerquin-Kern, Jean-Luc
Bernard-Pierrot, Isabelle
Garrido, Sergio Marco
Piguel, Sandrine
BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (20) : 5510 - 5530
[23] Imidazo[4,5-b]phenazines as Dual Topoisomerase I/IIa Inhibitors: Design, Synthesis, Biological Evaluation and Molecular Docking
Ghannam, Iman A. Y.
El Kerdawy, Ahmed M.
Abdel-Mohsen, Heba T.
EGYPTIAN JOURNAL OF CHEMISTRY, 2022, 65 (13): : 1157 - 1174
[24] Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5-b]pyridin-2-ylthioacetanilides as Potent HIV NNRTIs Via a Structure-based Bioisosterism Approach
Li, Xiao
Huang, Boshi
Zhou, Zhongxia
Gao, Ping
Pannecouque, Christophe
Daelemans, Dirk
De Clercq, Erik
Zhan, Peng
Liu, Xinyong
CHEMICAL BIOLOGY & DRUG DESIGN, 2016, 88 (02) : 241 - 253
[25] Nonpeptidal P-2 ligands for HIV protease inhibitors: Structure-based design, synthesis, and biological evaluation
Ghosh, AK
Kincaid, JF
Walters, DE
Chen, Y
Chaudhuri, NC
Thompson, WJ
Culberson, C
Fitzgerald, PMD
Lee, HY
McKee, SP
Munson, PM
Duong, TT
Darke, PL
Zugay, JA
Schleif, WA
Axel, MG
Lin, J
Huff, JR
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (17) : 3278 - 3290
[26] Structure-based design, synthesis, and biological evaluation of RGS4 inhibitors.
Jin, YF
Zhong, HL
Omnaas, JR
Neubig, RR
Mosberg, HI
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U39 - U39
[27] Design of potent and selective 2-aminobenzimidazole-based p38α MAP kinase inhibitors with excellent in vivo efficacy
de Dios, A
Shih, C
de Uralde, BL
Sánchez, C
Del Prado, M
Cabrejas, LMM
Pleite, S
Blanco-Urgoiti, J
Lorite, MJ
Nevill, CR
Bonjouklian, R
York, J
Vieth, M
Wang, Y
Magnus, N
Campbell, RM
Anderson, BD
McCann, DJ
Giera, DD
Lee, PA
Schultz, RM
Li, LC
Johnson, LM
Wolos, JA
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (07) : 2270 - 2273
[28] Design and Optimization of Novel Benzimidazole- and Imidazo[4,5-b]pyridine-Based ATM Kinase Inhibitors with Subnanomolar Activities
Dimitrov, Teodor
Moschopoulou, Athina Anastasia
Seidel, Lennart
Kronenberger, Thales
Kudolo, Mark
Poso, Antti
Geibel, Christian
Woelffing, Pascal
Dauch, Daniel
Zender, Lars
Schollmeyer, Dieter
Bajorath, Juergen
Forster, Michael
Laufer, Stefan
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (11) : 7304 - 7330
[29] P38 MAP kinase inhibitors: Evolution of imidazole-based and pyrido-pyrimidin-2-one lead classes
Natarajan, SR
Doherty, JB
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (10) : 987 - 1003
[30] Structure-based design, synthesis and crystallization of 2-arylquinazolines as lipid pocket ligands of p38α MAPK
Buehrmann, Mike
Wiedemann, Bianca M.
Mueller, Matthias P.
Hardick, Julia
Ecke, Maria
Rauh, Daniel
PLOS ONE, 2017, 12 (09):

← 1 2 3 4 5 →